Microbix Biosystems Inc. (MBX.TO) has seen a slight dip this week amid recent performance updates and strategic initiatives.
Microbix Biosystems Inc. has experienced a modest decline of 1.69% over the past week, closing at C$0.29 on the latest trading day. The company has made headlines with updates related to its financial performance and strategic initiatives, which could influence investor sentiment moving forward.
Advertisement
Microbix Biosystems Inc.
MBX.TO
MBX.TO
Microbix Biosystems Inc.
WealthAwesomeMarket cap
$39.88M
52W high
$0.32
52W low
$0.21
1W change
-1.69%
Beta
0.57
Analyst Price Targets
Based on analyst covering MBX
Wall Street analysts forecast MBX stock price to rise 37.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.40
+37.9% Upside
Current Price
C$0.29
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MBX's historical volatility
30-Day Vol
39.4%
Annualized
90-Day Vol
50.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.35
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.31 | C$0.27 – C$0.35 |
| 60 trading days | C$0.33 | C$0.27 – C$0.40 |
| 90 trading days | C$0.35 | C$0.27 – C$0.44 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider the company's recent performance metrics and strategic moves, including its latest earnings report and management incentives, when evaluating Microbix Biosystems Inc.'s stock.
C$0.29 close with a 1D % change of 0.00%
The stock has a market cap of approximately C$39.9 million and a 52-week trading range between C$0.21 and C$0.32, indicating potential volatility.
Bull case
The company reported a 13% increase in Q1 revenues, suggesting growth momentum. Additionally, they have initiated a Normal Course Issuer Bid to enhance shareholder value.
Bear case
Despite the recent revenue growth, the company continues to operate at a loss, with a profit margin of -38.6% and negative return on equity, which may raise concerns for investors.
Recent Performance Overview
Advertisement
Microbix Biosystems Inc. closed at C$0.29, showing no change in price for the day. Over the past week, the stock has decreased by 1.69%, and it has declined by 4.92% over the past month. Year-to-date, however, the stock has gained 20.83%, reflecting a positive trend despite recent fluctuations.
Recent Company News
While there were no major news releases this week, Microbix has been active in the past few months. Notably, the company reported Q1 2026 revenues of $4.2 million, marking a 13% increase from the previous quarter. They also initiated a Normal Course Issuer Bid to repurchase up to 5% of their outstanding shares, suggesting a focus on enhancing shareholder value.
Technical Picture
From a technical standpoint, Microbix's stock is currently trading at its 50-day moving average of C$0.29, indicating stability in that range. The 200-day moving average stands at C$0.25, showing a positive trend of 13.9% compared to the current price. The stock has a beta of 0.57, suggesting lower volatility compared to the broader market. With a 52-week trading range of C$0.21 to C$0.32, the stock is currently at 73% of its range.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
